pdp-pyrazinamide
aft pharmaceuticals ltd - pyrazinamide 500mg; - tablet - 500 mg - active: pyrazinamide 500mg excipient: colloidal silicon dioxide microcrystalline cellulose pregelatinised maize starch starch stearic acid - pdp-pyrazinamide is indicated in patients with active tuberculosis caused by mycobacterium tuberculosis. pdp-pyrazinamide is not active against the atypical mycobacteria. pdp-pyrazinamide should be given only in combination with other effective anti-tuberculous agents.
pyrazinamide tablets 500mg
macleods pharma uk ltd wynyard park house, wynyard avenue, wynyard, billingham ts22 5tb , united kingdom - pyrazinamide - tablet - pyrazinamide 500 mg - antimycobacterials
pyrazinamide tablets
macleods pharmaceuticals ltd. - pyrazinamide - tablets - 400mg
pyrazinamide tablet
macleods pharmaceuticals limited - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug- susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease cont
pyrazinamide tablet
major pharmaceuticals - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr
pyrazinamide 500mg tablets
macleods pharma uk ltd - pyrazinamide - oral tablet - 500mg
pyrazinamide tablet
novitium pharma llc - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr
pyrazinamide- pyrazinamide tablet tablet
marlex pharmaceuticals, inc - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease control (cdc) and american thoracic society for complete regimen and dosage recommendations. 4 pyrazinamide is contraindicated in persons: - with severe hepatic damage. - who have shown hypersensitivity to it. - with acute gout.
pyrazinamide- pyrazinamide powder
attix pharmaceuticals - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 5 kg in 5 kg
pyrazinamide tablets bp 400 mg
macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - pyrazinamide bp - tablet - pyrazinamide bp 400 mg - antimycobacterials: other drugs for treatment of